+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Point Of Care Diagnostics Market Size, Share & Trends Analysis Report By Product (Infectious Diseases, Glucose Testing, Cardiac Markers), By End-use (Clinics, Home, Hospitals), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • October 2023
  • Region: Asia Pacific
  • Grand View Research
  • ID: 5899540
The Asia Pacific point of care diagnostics market is expected to reach USD 15.61 billion by 2030, registering a CAGR of 8.1%. Growing base of geriatric population and the ability to render immediate results and improve patient care coupled with a rising market penetration of PACS (picture archiving and communication systems) and EMR (electronic medical records) are expected to drive demand over the next six years. Skilled staff shortages, especially pertaining to the field of diagnostics are also expected to accelerate the market penetration rates of point of care (PoC) products, by expediting lab automation processes. Rising demand for home healthcare and other healthcare establishments catering to the elderly population and initiatives undertaken by governments to shorten hospital stays by establishing out-patient care models are also expected to be key market factors.

The rapidly growing use of point of care diagnostic products has introduced a decentralization trend in the overall healthcare industry. Healthcare facilities and patients, in an attempt to attain or cater medical facilities remotely, encourage early diagnosis and curb costs are now decentralizing their facilities. Furthermore, these trends have also triggered the establishment of remote and stand-alone diagnostic facilities.

Asia Pacific Point Of Care Diagnostics Market Report Highlights

  • The infectious diseases segment dominated the market with the highest revenue share in 2022 owing to the increasing adoption of point of care diagnostics as a substitute for traditional laboratory testing in infectious diseases applications.
  • The cancer markers segment is expected to grow at the fastest CAGR over the forecast period from 2023 to 2030. The Asia Pacific region has experienced a notable rise in the prevalence of cancer in recent years.
  • The clinics segment held the largest revenue share of over 35% in 2022. Clinics are essential in providing healthcare services, particularly in remote and underserved areas.
  • China dominated the Asia Pacific PoC diagnostics market with a revenue share of over 40% in 2022. China has the world's largest population and faces notable challenges related to the prevalence of chronic and infectious diseases within its borders resulting in an increasing demand for point-of-care diagnostics.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. End Use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. End-Use Outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Asia Pacific Point Of Care Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Point Of Care Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic Landscape
Chapter 4. Asia Pacific Point Of Care Diagnostics: Product Estimates & Trend Analysis
4.1. Point Of Care Diagnostics Market: Key Takeaways
4.2. Point Of Care Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Glucose Testing
4.3.1. Glucose testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Hb1Ac Testing
4.4.1. Hb1Ac testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Coagulation
4.5.1. Coagulation market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Fertility/Pregnancy
4.6.1. Fertility/Pregnancy market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Infectious Diseases
4.7.1. Infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.2. HIV POC
4.7.2.1. HIV POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.3. Clostridium Difficile POC
4.7.3.1. Clostridium difficile POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.4. HBV POC
4.7.4.1. HBV POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.5. Pneumonia or Streptococcus Associated Infections
4.7.5.1. Pneumonia or streptococcus associated infections market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.6. Respiratory Syncytial Virus (RSV) POC
4.7.6.1. Respiratory syncytial virus (RSV) POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.7. HPV POC
4.7.7.1. HPV POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.8. Influenza/Flu POC
4.7.8.1. Influenza/Flu POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.9. HCV POC
4.7.9.1. HCV POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.10. MRSA POC
4.7.10.1. MRSA POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.11. TB and Drug-resistant TB POC
4.7.11.1. TB and drug-resistant TB POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.12. HSV POC
4.7.12.1. HSV POC market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.13. COVID-19
4.7.13.1. COVID-19 market estimates and forecasts, 2018 to 2030 (USD Million)
4.7.14. Other Infectious Diseases
4.7.14.1. Other infectious diseases market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Cardiac Markers
4.8.1. Cardiac markers market estimates and forecasts, 2018 to 2030 (USD Million)
4.9. Thyroid Stimulating Hormone
4.9.1. Thyroid stimulating hormone market estimates and forecasts, 2018 to 2030 (USD Million)
4.10. Hematology
4.10.1. Hematology stimulating hormone market estimates and forecasts, 2018 to 2030 (USD Million)
4.11. Primary Care Systems
4.11.1. Primary care systems market estimates and forecasts, 2018 to 2030 (USD Million)
4.12. Decentralized Clinical Chemistry
4.12.1. Decentralized clinical chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
4.13. Feces
4.13.1. Feces market estimates and forecasts, 2018 to 2030 (USD Million)
4.14. Lipid Testing
4.14.1. Lipid testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.15. Cancer Marker
4.15.1. Cancer marker market estimates and forecasts, 2018 to 2030 (USD Million)
4.16. Blood Gas/Electrolytes
4.16.1. Blood gas/electrolytes market estimates and forecasts, 2018 to 2030 (USD Million)
4.17. Ambulatory Chemistry
4.17.1. Ambulatory chemistry market estimates and forecasts, 2018 to 2030 (USD Million)
4.18. Drug Abuse Testing
4.18.1. Drug abuse testing market estimates and forecasts, 2018 to 2030 (USD Million)
4.19. Autoimmune Disease
4.19.1. Autoimmune disease market estimates and forecasts, 2018 to 2030 (USD Million)
4.20. Urinalysis/Nephrology
4.20.1. Urinalysis/Nephrology market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Asia Pacific Point Of Care Diagnostics Market: End Use Estimates & Trend Analysis
5.1. Point Of Care Diagnostics Market: Key Takeaways
5.2. Point Of Care Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Clinics
5.3.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.2. Physician Office
5.3.2.1. Physician office market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.3. Pharmacy and Retail Clinics
5.3.3.1. Pharmacy and retail clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.4. Non-practice Clinics
5.3.4.1. Non-practice clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.3.5. Urgent Care Clinics
5.3.5.1. Urgent care clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Hospitals
5.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Home
5.5.1. Home market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Assisted Living Healthcare Facilities
5.6.1. Assisted living healthcare facilities market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Laboratory
5.7.1. Laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Asia Pacific Point Of Care Diagnostics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Point Of Care Diagnostics Market by Region: Key Marketplace Takeaway
6.3. Asia Pacific
6.3.1. China
6.3.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. Japan
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. India
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.4. South Korea
6.3.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.5. Australia
6.3.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.6. Thailand
6.3.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.7. New Zealand
6.3.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.8. Singapore
6.3.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.9. Vietnam
6.3.9.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Wipro
7.2.1.1. Company Overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. ZOE Limited
7.2.2.1. Company Overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Vocalis Health
7.2.3.1. Company Overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. DarwinAI
7.2.4.1. Company Overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Biocogniv Inc.
7.2.5.1. Company Overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Laipac Technology Inc.
7.2.6.1. Company Overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Gauss Surgical, Inc.
7.2.7.1. Company Overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Oxford Immune Algorithmics Ltd
7.2.8.1. Company Overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. F. Hoffmann-La Roche Ltd.
7.2.9.1. Company Overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. QIAGEN
7.2.10.1. Company Overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Danaher
7.2.11.1. Company Overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Beckman Coulter, Inc.
7.2.12.1. Company Overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Radiometer Medical ApS
7.2.13.1. Company Overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. HemoCue AB
7.2.14.1. Company Overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. BD (Becton, Dickinson, and Company)
7.2.15.1. Company Overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. BIOMÉRIEUX
7.2.16.1. Company Overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives
7.2.17. Abbott
7.2.17.1. Company Overview
7.2.17.2. Financial performance
7.2.17.3. Product benchmarking
7.2.17.4. Strategic initiatives
7.2.18. Siemens Healthcare GmbH
7.2.18.1. Company Overview
7.2.18.2. Financial performance
7.2.18.3. Product benchmarking
7.2.18.4. Strategic initiatives
7.2.19. Zoetis Services LLC
7.2.19.1. Company Overview
7.2.19.2. Financial performance
7.2.19.3. Product benchmarking
7.2.19.4. Strategic initiatives
7.2.20. Abaxis
7.2.20.1. Company Overview
7.2.20.2. Financial performance
7.2.20.3. Product benchmarking
7.2.20.4. Strategic initiatives
7.2.21. Instrumentation Laboratory Company
7.2.21.1. Company Overview
7.2.21.2. Financial performance
7.2.21.3. Product benchmarking
7.2.21.4. Strategic initiatives
7.2.22. Nova Biomedical
7.2.22.1. Company Overview
7.2.22.2. Financial performance
7.2.22.3. Product benchmarking
7.2.22.4. Strategic initiatives
7.2.23. Trividia Health, Inc.
7.2.23.1. Company Overview
7.2.23.2. Financial performance
7.2.23.3. Product benchmarking
7.2.23.4. Strategic initiatives
7.2.24. Quidel Corporation
7.2.24.1. Company Overview
7.2.24.2. Financial performance
7.2.24.3. Product benchmarking
7.2.24.4. Strategic initiatives
7.2.25. Trinity Biotech
7.2.25.1. Company Overview
7.2.25.2. Financial performance
7.2.25.3. Product benchmarking
7.2.25.4. Strategic initiatives
7.2.26. SEKISUI Diagnostics
7.2.26.1. Company Overview
7.2.26.2. Financial performance
7.2.26.3. Product benchmarking
7.2.26.4. Strategic initiatives
7.2.27. Orasure Technologies, Inc.
7.2.27.1. Company Overview
7.2.27.2. Financial performance
7.2.27.3. Product benchmarking
7.2.27.4. Strategic initiatives
7.2.28. Nipro Europe Group Companies
7.2.28.1. Company Overview
7.2.28.2. Financial performance
7.2.28.3. Product benchmarking
7.2.28.4. Strategic initiatives
7.2.29. Spectral Medical Inc.
7.2.29.1. Company Overview
7.2.29.2. Financial performance
7.2.29.3. Product benchmarking
7.2.29.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 Asia Pacific point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 3 Asia Pacific point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 4 Asia Pacific point of care diagnostics market, by region, 2018-2030 (USD Million)
Table 5 China point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 6 China point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 7 Japan point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 8 Japan point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 9 India point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 10 India point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 11 Australia point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 12 Australia point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 13 Thailand point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 14 Thailand point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 15 New Zealand point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 16 New Zealand point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 17 Singapore point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 18 Singapore point of care diagnostics market, by end-use, 2018-2030 (USD Million)
Table 19 Vietnam point of care diagnostics market, by product, 2018-2030 (USD Million)
Table 20 Vietnam point of care diagnostics market, by end-use, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Point of care diagnostics: Market outlook
Fig. 9 Point of care diagnostics: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Point of care diagnostics market driver impact
Fig. 15 Point of care diagnostics market restraint impact
Fig. 16 Point of care diagnostics market strategic initiatives analysis
Fig. 17 Point of care diagnostics market: Product movement analysis
Fig. 18 Point of care diagnostics market: Product outlook and key takeaways
Fig. 19 Glucose testing market estimates and forecasts, 2018-2030
Fig. 20 Hb1Ac testing market estimates and forecasts, 2018-2030
Fig. 21 Coagulation market estimates and forecasts, 2018-2030
Fig. 22 Fertility/Pregnancy market estimates and forecasts, 2018-2030
Fig. 23 Infectious diseases market estimates and forecasts, 2018-2030
Fig. 24 Cardiac markers market estimates and forecasts, 2018-2030
Fig. 25 Thyroid stimulating hormone market estimates and forecasts, 2018-2030
Fig. 26 Hematology market estimates and forecasts, 2018-2030
Fig. 27 Primary care systems market estimates and forecasts, 2018-2030
Fig. 28 Decentralized clinical chemistry market estimates and forecasts, 2018-2030
Fig. 29 Feces market estimates and forecasts, 2018-2030
Fig. 30 Lipid testing market estimates and forecasts, 2018-2030
Fig. 31 Cancer marker market estimates and forecasts, 2018-2030
Fig. 32 Blood gas/electrolytes market estimates and forecasts, 2018-2030
Fig. 33 Ambulatory chemistry market estimates and forecasts, 2018-2030
Fig. 34 Drug abuse testing market estimates and forecasts, 2018-2030
Fig. 35 Autoimmune disease market estimates and forecasts, 2018-2030
Fig. 36 Urinalysis/Nephrology market estimates and forecasts, 2018-2030
Fig. 37 Point of care diagnostics market: End-use movement analysis
Fig. 38 Point of care diagnostics market: End-use outlook and key takeaways
Fig. 39 Clinics market estimates and forecasts, 2018-2030
Fig. 40 Hospital market estimates and forecasts, 2018-2030
Fig. 41 Home market estimates and forecasts, 2018-2030
Fig. 42 Assisted living healthcare facilities market estimates and forecasts, 2018-2030
Fig. 43 Laboratory market estimates and forecasts, 2018-2030
Fig. 44 Asia Pacific point of care diagnostics market: Regional movement analysis
Fig. 45 Asia Pacific point of care diagnostics market: Regional outlook and key takeaways
Fig. 46 China market estimates and forecasts, 2018-2030
Fig. 47 Japan market estimates and forecasts, 2018-2030
Fig. 48 India market estimates and forecasts, 2018-2030
Fig. 49 South Korea market estimates and forecasts, 2018-2030
Fig. 50 Australia market estimates and forecasts, 2018-2030
Fig. 51 Thailand market estimates and forecasts, 2018-2030
Fig. 52 New Zealand market estimates and forecasts, 2018-2030
Fig. 53 Singapore market estimates and forecasts, 2018-2030
Fig. 54 Vietnam market estimates and forecasts, 2018-2030

Companies Mentioned

  • Wipro
  • ZOE Limited
  • Vocalis Health
  • DarwinAI
  • Biocogniv Inc.
  • Laipac Technology Inc.
  • Gauss Surgical, Inc.
  • Oxford Immune Algorithmics Ltd
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN
  • Danaher
  • Beckman Coulter, Inc.
  • Radiometer Medical ApS
  • HemoCue AB
  • BD (Becton, Dickinson, and Company)
  • BIOMÉRIEUX
  • Abbott
  • Siemens Healthcare GmbH
  • Zoetis Services LLC
  • Abaxis
  • Instrumentation Laboratory Company
  • Nova Biomedical
  • Trividia Health, Inc.
  • Quidel Corporation
  • Trinity Biotech
  • SEKISUI Diagnostics
  • Orasure Technologies, Inc.
  • Nipro Europe Group Companies
  • Spectral Medical Inc.

Methodology

Loading
LOADING...

Table Information